{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T11:29:39Z","timestamp":1775129379392,"version":"3.50.1"},"reference-count":63,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["(82160524)"],"award-info":[{"award-number":["(82160524)"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Health Commission of Yunnan Province Project","award":["(2017NS188)"],"award-info":[{"award-number":["(2017NS188)"]}]},{"name":"the \u00e2\u20ac\u0153Famous Doctor\u00e2\u20ac\u009d Special Project of Ten Thousand People Plan of Yunnan Province","award":["(CZ0096)"],"award-info":[{"award-number":["(CZ0096)"]}]},{"name":"the innovative research team of Yunnan Province","award":["(202305AS350020)"],"award-info":[{"award-number":["(202305AS350020)"]}]},{"name":"the Basic research in Yunnan Province","award":["202201AY070001-138"],"award-info":[{"award-number":["202201AY070001-138"]}]},{"name":"the Basic research in Yunnan Province","award":["202201AY070001-162"],"award-info":[{"award-number":["202201AY070001-162"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:p>Carriers with germline breast cancer 1\/2 gene mutations (<jats:italic toggle=\"yes\">BRCA<\/jats:italic>m) are likely to develop ovarian cancer (OC). Therefore, identifying these mutations may enable individualized therapy for OC and preventive measures to reduce OC risk in <jats:italic toggle=\"yes\">BRCA<\/jats:italic>m carrier families. Thus, we investigated the prevalence of <jats:italic toggle=\"yes\">BRCA<\/jats:italic>m in OC patients from Yunnan Province in Southwest China. In total, 674 unselected OC patients were enrolled and tested for <jats:italic toggle=\"yes\">BRCA<\/jats:italic>m via next-generation sequencing. Data on clinicopathological characteristics and personal\/family history of cancer were collected. The prevalence rates of pathogenic\/likely pathogenic <jats:italic toggle=\"yes\">BRCA<\/jats:italic>m were 26.6% overall, 20.8% among <jats:italic toggle=\"yes\">BRCA1<\/jats:italic>m carriers, 5.5% among <jats:italic toggle=\"yes\">BRCA2<\/jats:italic>m carriers, and 0.3% among carriers of both <jats:italic toggle=\"yes\">BRCA1<\/jats:italic>m and <jats:italic toggle=\"yes\">BRCA2<\/jats:italic>m. The most common pathogenic mutation in the <jats:italic toggle=\"yes\">BRCA1<\/jats:italic> gene was c.5114T&gt;C (<jats:italic toggle=\"yes\">n<\/jats:italic>\u2005=\u20059). The number of <jats:italic toggle=\"yes\">BRCA<\/jats:italic>m carriers was significantly greater among patients with serous cancer, a personal tumor history, a family history of hereditary breast and ovarian cancer (HBOC)-related tumors, and bilateral tumors. The most common pathogenic mutation in this cohort was c.5114T&gt;C (<jats:italic toggle=\"yes\">n<\/jats:italic>\u2005=\u20059) in <jats:italic toggle=\"yes\">BRCA1<\/jats:italic>. The prevalence and spectrum of <jats:italic toggle=\"yes\">BRCA<\/jats:italic>m in OC patients from Yunnan Province are different from those in other groups. <jats:italic toggle=\"yes\">BRCA<\/jats:italic> status testing is advised for all OC patients, particularly those with a family history of HBOC.<\/jats:p>","DOI":"10.1097\/cej.0000000000000931","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T14:00:41Z","timestamp":1731074441000},"page":"231-240","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Prevalence of BRCA1 and BRCA2 mutations in ovarian cancer patients from Yunnan Province in southwest China"],"prefix":"10.1097","volume":"34","author":[{"given":"Yongmei","family":"Peng","sequence":"first","affiliation":[{"name":"Department of Gynecology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaqian","family":"Liao","sequence":"additional","affiliation":[{"name":"The Second Department of Breast Surgery"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xian","family":"He","sequence":"additional","affiliation":[{"name":"Department of Gynecology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongchun","family":"Zhou","sequence":"additional","affiliation":[{"name":"Molecular Diagnosis Center of Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming, Yunnan Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gynecology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Gynecology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongying","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Gynecology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,10,25]]},"reference":[{"key":"R1-20250327","doi-asserted-by":"crossref","first-page":"14906","DOI":"10.1038\/s41598-021-94403-1","article-title":"Prevalence and predictors of germline BRCA1 and BRCA2 mutations among young patients with breast cancer in Jordan.","volume":"11","author":"Abdel-Razeq","year":"2021","journal-title":"Sci Rep"},{"key":"R2-20250327","doi-asserted-by":"crossref","first-page":"e2125","DOI":"10.1002\/mgg3.2125","article-title":"Prevalence and clinical implications of germline mutations among Jordanian patients with ovarian cancer. The Jordanian exploratory cancer genetics (Jo-ECAG) ovarian study.","volume":"11","author":"Abdel-Razeq","year":"2023","journal-title":"Mol Genet Genomic Med"},{"key":"R3-20250327","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s10549-008-9961-0","article-title":"BRCA1 2080insA mutation in familial breast cancer.","volume":"113","author":"Alansari","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"R4-20250327","first-page":"3035","article-title":"Breast cancer in Pakistan a critical appraisal of the situation regarding female health and where the nation stands?","volume":"17","author":"Basra","year":"2016","journal-title":"Asian Pac J Cancer Prev"},{"key":"R5-20250327","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13048-015-0124-8","article-title":"A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population.","volume":"8","author":"Belanger","year":"2015","journal-title":"J Ovarian Res"},{"key":"R6-20250327","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/ijc.32176","article-title":"Germline variation in BRCA1\/2 is highly ethnic-specific: evidence from over 30,000 Chinese hereditary breast and ovarian cancer patients.","volume":"145","author":"Bhaskaran","year":"2019","journal-title":"Int J Cancer"},{"key":"R7-20250327","doi-asserted-by":"crossref","first-page":"E1200","DOI":"10.1002\/humu.21202","article-title":"Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study.","volume":"31","author":"Borg","year":"2010","journal-title":"Hum Mutat"},{"key":"R8-20250327","doi-asserted-by":"crossref","first-page":"77","DOI":"10.6004\/jnccn.2021.0001","article-title":"Genetic\/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology.","volume":"19","author":"Daly","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"R9-20250327","doi-asserted-by":"crossref","first-page":"941375","DOI":"10.3389\/fgene.2022.941375","article-title":"Detection of BRCA1\/2 pathogenic variants in patients with breast and\/or ovarian cancer and their families. Analysis of 3,458 cases from Lower Silesia (Poland) according to the diagnostic algorithm of the National Cancer Control Programme.","volume":"13","author":"Doraczynska-Kowalik","year":"2022","journal-title":"Front Genet"},{"key":"R10-20250327","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-018-0461-z","article-title":"Accurate classification of BRCA1 variants with saturation genome editing.","volume":"562","author":"Findlay","year":"2018","journal-title":"Nature"},{"key":"R11-20250327","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s10689-017-9985-x","article-title":"Molecular characterization and clinical interpretation of BRCA1\/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.","volume":"16","author":"Gabald\u00f3 Barrios","year":"2017","journal-title":"Fam Cancer"},{"key":"R12-20250327","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/humu.23965","article-title":"Comprehensive profiling of BRCA1 and BRCA2 variants in breast and ovarian cancer in Chinese patients.","volume":"41","author":"Gao","year":"2020","journal-title":"Hum Mutat"},{"key":"R13-20250327","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/JCO.2009.25.1082","article-title":"Increased incidence of visceral metastases in Scottish patients with BRCA1\/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype.","volume":"28","author":"Gourley","year":"2010","journal-title":"J Clin Oncol"},{"key":"R14-20250327","doi-asserted-by":"crossref","first-page":"BSR20182471","DOI":"10.1042\/BSR20182471","article-title":"Identifying a BRCA2 c.5722_5723del mutation in a Han-Chinese family with breast cancer.","volume":"39","author":"Guo","year":"2019","journal-title":"Biosci Rep"},{"key":"R15-20250327","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2174\/0115680096271476231226174810","article-title":"Real-world study on the effect of PARPi as maintenance therapy on platinum sensitivity after first- and second-line chemotherapy in patients with recurrent high-grade serous epithelial ovarian cancer.","volume":"24","author":"Guo","year":"2024","journal-title":"Curr Cancer Drug Targets"},{"key":"R16-20250327","doi-asserted-by":"crossref","first-page":"S554","DOI":"10.1016\/S0959-8049(16)31537-4","article-title":"BRCA1 and BRCA2 mutations in 1691 epithelial ovarian tumors identify subgroups with distinct molecular characteristics.","volume":"51","author":"Herzog","year":"2015","journal-title":"Eur J Cancer"},{"key":"R17-20250327","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.hoc.2018.07.004","article-title":"Pathogenesis, genetics, and genomics of non-high grade serous ovarian cancers.","volume":"32","author":"Ilenkovan","year":"2018","journal-title":"Hematol Oncol Clin North Am"},{"key":"R18-20250327","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10549-022-06782-2","article-title":"A spectrum of BRCA1 and BRCA2 germline deleterious variants in ovarian cancer in Russia.","volume":"197","author":"Kechin","year":"2023","journal-title":"Breast Cancer Res Treat"},{"key":"R19-20250327","doi-asserted-by":"crossref","first-page":"303","DOI":"10.5603\/RPOR.a2022.0030","article-title":"The highest frequency of BRCA1 c.3700_3704del detected among Albanians from Kosovo.","volume":"27","author":"Kostovska","year":"2022","journal-title":"Rep Pract Oncol Radiother"},{"key":"R20-20250327","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ygyno.2018.05.011","article-title":"Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation.","volume":"150","author":"Kotsopoulos","year":"2018","journal-title":"Gynecol Oncol"},{"key":"R21-20250327","doi-asserted-by":"crossref","first-page":"m3773","DOI":"10.1136\/bmj.m3773","article-title":"Treatment of epithelial ovarian cancer.","volume":"371","author":"Kuroki","year":"2020","journal-title":"BMJ"},{"key":"R22-20250327","doi-asserted-by":"crossref","first-page":"941","DOI":"10.4143\/crt.2018.312","article-title":"Clinical and genetic characteristics of BRCA1\/2 mutation in Korean ovarian cancer patients: a multicenter study and literature review.","volume":"51","author":"Kwon","year":"2019","journal-title":"Cancer Res Treat"},{"key":"R23-20250327","doi-asserted-by":"crossref","first-page":"1002360","DOI":"10.3389\/fonc.2022.1002360","article-title":"Overview on population screening for carriers with germline BRCA mutation in China.","volume":"12","author":"Lei","year":"2022","journal-title":"Front Oncol"},{"key":"R24-20250327","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/2047-783X-19-35","article-title":"The prevalence of BRCA1\/2 mutations of triple-negative breast cancer patients in Xinjiang multiple ethnic region of China.","volume":"19","author":"Li","year":"2014","journal-title":"Eur J Med Res"},{"key":"R25-20250327","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ygyno.2018.07.024","article-title":"BRCA germline mutations in an unselected nationwide cohort of Chinese patients with ovarian cancer and healthy controls.","volume":"151","author":"Li","year":"2018","journal-title":"Gynecol Oncol"},{"key":"R26-20250327","doi-asserted-by":"crossref","first-page":"655709","DOI":"10.3389\/fonc.2021.655709","article-title":"Identification of BRCA1:c.5470_5477del as a founder mutation in Chinese ovarian cancer patients.","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"key":"R27-20250327","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13045-020-01010-0","article-title":"Prevalence and reclassification of BRCA1 and BRCA2 variants in a large, unselected Chinese Han breast cancer cohort.","volume":"14","author":"Liu","year":"2021","journal-title":"J Hematol Oncol"},{"key":"R28-20250327","doi-asserted-by":"crossref","first-page":"101974","DOI":"10.1016\/j.legalmed.2021.101974","article-title":"Genetic polymorphisms of 16 X-STR loci analyzed in the Han population of Yunnan Province, Southwest China.","volume":"54","author":"Liu","year":"2022","journal-title":"Leg Med (Tokyo)"},{"key":"R29-20250327","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000535012","article-title":"BRCA mutation patients: are there other predisposing factors for ovarian cancer occurrence? a multicenter retrospective study.","volume":"89","author":"Loizzi","year":"2024","journal-title":"Gynecol Obstet Invest"},{"key":"R30-20250327","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/1471-2407-8-140","article-title":"Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and\/or ovarian cancer.","volume":"8","author":"Machackova","year":"2008","journal-title":"BMC Cancer"},{"key":"R31-20250327","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/humu.9174","article-title":"Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and\/or ovarian cancer families in Southern Germany.","volume":"22","author":"Meyer","year":"2003","journal-title":"Hum Mutat"},{"key":"R32-20250327","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.1038\/s41467-018-06581-8","article-title":"Germline pathogenic variants of 11 breast cancer genes in 7,051 Japanese patients and 11,241 controls.","volume":"9","author":"Momozawa","year":"2018","journal-title":"Nat Commun"},{"key":"R33-20250327","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer.","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"key":"R34-20250327","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13053-021-00190-1","article-title":"Significant detection of new germline pathogenic variants in Australian Pancreatic Cancer Screening Program participants.","volume":"19","author":"Murali","year":"2021","journal-title":"Hered Cancer Clin Pract"},{"key":"R35-20250327","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.3390\/genes13071286","article-title":"Germline testing in a cohort of patients at high risk of hereditary cancer predisposition syndromes: first two-year results from south Italy.","volume":"13","author":"Paduano","year":"2022","journal-title":"Genes"},{"key":"R36-20250327","doi-asserted-by":"crossref","first-page":"9188","DOI":"10.1038\/s41598-018-27315-2","article-title":"The germline mutational landscape of BRCA1 and BRCA2 in Brazil.","volume":"8","author":"Palmero","year":"2018","journal-title":"Sci Rep"},{"key":"R37-20250327","doi-asserted-by":"crossref","first-page":"R728","DOI":"10.1186\/bcr1282","article-title":"High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area.","volume":"7","author":"Pohlreich","year":"2005","journal-title":"Breast Cancer Res"},{"key":"R38-20250327","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1136\/jmedgenet-2020-107181","article-title":"Can population BRCA screening be applied in non-Ashkenazi Jewish populations? Experience in Macau population.","volume":"58","author":"Qin","year":"2021","journal-title":"J Med Genet"},{"key":"R39-20250327","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1056\/NEJMoa012158","article-title":"Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.","volume":"346","author":"Rebbeck","year":"2002","journal-title":"N Engl J Med"},{"key":"R40-20250327","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/humu.23406","article-title":"Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations.","volume":"39","author":"Rebbeck","year":"2018","journal-title":"Hum Mutat"},{"key":"R41-20250327","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"R42-20250327","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/annonc\/mdr321","article-title":"Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives.","volume":"23","author":"Sehouli","year":"2012","journal-title":"Ann Oncol"},{"key":"R43-20250327","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/cas.14242","article-title":"Prevalence of hereditary breast and ovarian cancer (HBOC) predisposition gene mutations among 882 HBOC high-risk Chinese individuals.","volume":"111","author":"Shao","year":"2020","journal-title":"Cancer Sci"},{"key":"R44-20250327","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1002\/ijc.30633","article-title":"BRCA1 and BRCA2 mutations in ovarian cancer patients from China: ethnic-related mutations in BRCA1 associated with an increased risk of ovarian cancer.","volume":"140","author":"Shi","year":"2017","journal-title":"Int J Cancer"},{"key":"R45-20250327","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024.","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R46-20250327","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10549-018-4726-x","article-title":"Screening of over 1000 Indian patients with breast and\/or ovarian cancer with a multi-gene panel: prevalence of BRCA1\/2 and non-BRCA mutations.","volume":"170","author":"Singh","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"R47-20250327","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s11033-016-3968-0","article-title":"Evidence for a pathogenic role of BRCA1 L1705P and W1837X germ-line mutations.","volume":"43","author":"Sokolenko","year":"2016","journal-title":"Mol Biol Rep"},{"key":"R48-20250327","doi-asserted-by":"crossref","first-page":"4703","DOI":"10.1093\/hmg\/ddu172","article-title":"The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population.","volume":"23","author":"Song","year":"2014","journal-title":"Hum Mol Genet"},{"key":"R49-20250327","doi-asserted-by":"crossref","first-page":"42909","DOI":"10.1038\/srep42909","article-title":"\u03b2-globin gene cluster haplotypes in ethnic minority populations of southwest China.","volume":"7","author":"Sun","year":"2017","journal-title":"Sci Rep"},{"key":"R50-20250327","doi-asserted-by":"crossref","first-page":"6113","DOI":"10.1158\/1078-0432.CCR-16-3227","article-title":"Germline mutations in cancer susceptibility genes in a large series of unselected breast cancer patients.","volume":"23","author":"Sun","year":"2017","journal-title":"Clin Cancer Res"},{"key":"R51-20250327","doi-asserted-by":"crossref","first-page":"341723","DOI":"10.1155\/2015\/341723","article-title":"Hereditary ovarian cancer: not only BRCA 1 and 2 genes.","volume":"2015","author":"Toss","year":"2015","journal-title":"Biomed Res Int"},{"key":"R52-20250327","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1038\/s41436-018-0335-7","article-title":"Outcomes of 92 patient-driven family studies for reclassification of variants of uncertain significance.","volume":"21","author":"Tsai","year":"2019","journal-title":"Genet Med"},{"key":"R53-20250327","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7150\/ijms.5.197","article-title":"BRCA1 mutations in Algerian breast cancer patients: high frequency in young, sporadic cases.","volume":"5","author":"Uhrhammer","year":"2008","journal-title":"Int J Med Sci"},{"key":"R54-20250327","doi-asserted-by":"crossref","first-page":"188907","DOI":"10.1016\/j.bbcan.2023.188907","article-title":"An overview of the research progress of BRCA gene mutations in breast cancer.","volume":"1878","author":"Wan","year":"2023","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"R55-20250327","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1097\/IGC.0000000000001065","article-title":"The first nationwide multicenter prevalence study of germline BRCA1 and BRCA2 mutations in Chinese ovarian cancer patients.","volume":"27","author":"Wu","year":"2017","journal-title":"Int J Gynecol Cancer"},{"key":"R56-20250327","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1186\/s12885-024-12089-w","article-title":"Population-based BRCA germline mutation screening in the Han Chinese identifies individuals at risk of BRCA mutation-related cancer: experience from a clinical diagnostic center from greater Shanghai area.","volume":"24","author":"Wu","year":"2024","journal-title":"BMC Cancer"},{"key":"R57-20250327","first-page":"73","article-title":"Histopathological patterns of primary malignant ovarian neoplasms in different age groups in Almadinah Almunawwarah region, KSA.","volume":"14","author":"Yousif","year":"2019","journal-title":"J Taibah Univ Med Sci"},{"key":"R58-20250327","doi-asserted-by":"crossref","first-page":"10152","DOI":"10.3390\/curroncol30120739","article-title":"Beyond sterilization: a comprehensive review on the safety and efficacy of opportunistic salpingectomy as a preventative strategy for ovarian cancer.","volume":"30","author":"Zadabedini Masouleh","year":"2023","journal-title":"Curr Oncol"},{"key":"R59-20250327","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ygyno.2011.01.020","article-title":"Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer.","volume":"121","author":"Zhang","year":"2011","journal-title":"Gynecol Oncol"},{"key":"R60-20250327","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1186\/s12885-022-09943-0","article-title":"Germline variants profiling of BRCA1 and BRCA2 in Chinese Hakka breast and ovarian cancer patients.","volume":"22","author":"Zhang","year":"2022","journal-title":"BMC Cancer"},{"key":"R61-20250327","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13048-024-01381-9","article-title":"A real-world study of treatment patterns following disease progression in epithelial ovarian cancer patients undergoing poly-ADP-ribose polymerase inhibitor maintenance therapy.","volume":"17","author":"Zhang","year":"2024","journal-title":"J Ovarian Res"},{"key":"R62-20250327","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1158\/1078-0432.CCR-14-1816","article-title":"Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.","volume":"21","author":"Zhong","year":"2015","journal-title":"Clin Cancer Res"},{"key":"R63-20250327","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/14737140.2023.2298832","article-title":"Comparison of poly (ADP-ribose) polymerase inhibitors (PARPis) as maintenance therapy for newly-diagnosed and platinum-sensitive recurrent ovarian cancer with BRCA mutational status: a systematic review and network meta-analysis.","volume":"24","author":"Zhou","year":"2024","journal-title":"Expert Rev Anticancer Ther"}],"container-title":["European Journal of Cancer Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CEJ.0000000000000931","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T13:33:32Z","timestamp":1743341612000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CEJ.0000000000000931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,25]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/cej.0000000000000931","relation":{},"ISSN":["0959-8278","1473-5709"],"issn-type":[{"value":"0959-8278","type":"print"},{"value":"1473-5709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,25]]}}}